Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model
Open Access
- 1 January 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (1) , 203-210
- https://doi.org/10.1128/aac.46.1.203-210.2002
Abstract
An in vitro pharmacodynamic investigation was conducted to explore whether the area under the concentration time curve from 0 to 24 h (AUC 0–24 )/MIC ratio could predict fluoroquinolone performance against Bacteroides fragilis . An in vitro model was used to generate kill curves for trovafloxacin (TVA) and levofloxacin (LVX) at AUC 0–24 /MIC ratios of 1 to 406 against three strains of B. fragilis (ATCC 25285, ATCC 23745, and clinical isolate M97-117). TVA and LVX were bolused prior to the start of experiments to achieve the corresponding AUC 0–24 /MIC ratio. Experiments were performed in duplicate over 24 h and in an anaerobic environment. Analyses of antimicrobial performance were conducted by comparing the rates of bacterial kill (K) using nonlinear regression analysis with 95% confidence intervals. Statistical significance was defined as a lack of overlap in the 95% confidence limits generated from the slope of each kill curve. For both TVA and LVX, K was maximized once an AUC 0–24 /MIC ratio of ≥40 was achieved and was not further increased despite a 10-fold increase in AUC 0–24 /MIC from approximately 40 to 400 against all three strains of B. fragilis . No significant differences were found in K between AUC 0–24 /MIC ratios of approximately 40 to 200. In experiments where AUC 0–24 /MIC ratios that were ≥ 5 and ≤ 44 were conducted, 64% demonstrated regrowth at 24 h. Resistant strains were selected in 50% of those experiments, demonstrating regrowth, which resulted in increased MICs of two- to 16-fold for both TVA and LVX. Regrowth did not occur, nor were resistant strains selected in any studies with an AUC/MIC that was > 44. Our findings suggest that fluoroquinolones provide antibacterial effects against B. fragilis in a concentration-independent manner associated with an AUC 0–24 /MIC ratio of ≥40. Also, the potential for the selection of resistant strains of B. fragilis may increase with an AUC 0–24 /MIC ratio of ≤44.Keywords
This publication has 26 references indexed in Scilit:
- Fluoroquinolone Resistance in Anaerobic Bacteria following Exposure to Levofloxacin, Trovafloxacin, and Sparfloxacin in an In Vitro Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2001
- Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas , and Peptostreptococcus SpeciesAntimicrobial Agents and Chemotherapy, 2001
- What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?Clinical Infectious Diseases, 2001
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Possible Role for the New Fluoroquinolones (Levofloxacin, Grepafloxacin, Trovafloxacin, Clinafloxacin, Sparfloxacin, and DU-6859a) in the Treatment of Anaerobic Infections: Review of Current Information on Efficacy and SafetyClinical Infectious Diseases, 1996
- Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobesAntimicrobial Agents and Chemotherapy, 1994
- Wound and Intraabdominal Infections: Microbiological Considerations and Approaches to TreatmentClinical Infectious Diseases, 1993
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Pharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen DesignInfection Control & Hospital Epidemiology, 1990
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987